Karamvir Yadav, Medical Oncologist in Jaipur, India, shared posts on X about a recent article by Andrew Armstrong et al, adding:
“One step more towards precision oncology
Key PROpel biomarker message:
- 85% HRRm concordance
- 94% BRCAm concordance
- ctDNA success rate 92%
- Minimal false negatives
Liquid biopsy is reshaping first-line mCRPC decision-making.”
Title: Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial
Authors: Andrew Armstrong, Fred Saad, Mototsugu Oya, Neal Shore, Giuseppe Procopio, Cagatay Arslan, Niven Mehra, Emma Brown, Jae Young Joung, Mikio Sugimoto, Mustafa Özgüroğlu, Craig Gedye, Oliver Sartor, Christian Poehlein, Ping Qiu, Yu-Zhen Liu, Xiaodun Li, Elizabeth Harrington, David McGuinness, Jinyu Kang, Alan Barnicle, Noel Clarke
Read the Full Article on Journal of Clinical Oncology
More posts featuring Karamvir Yadav.
